Date: March 18th- 21st, 2024 Location: New York City, NY Archimica/PIHS will attend DCAT Week in New York from 18th to 21st March. We look forward to seeing you in our ...
PI Health Sciences announces the acquisition of Archimica S.p.A from Livia Group April 28, 2023 We are pleased to announce that today PI Health Sciences has acquired Archimica S.p.A (headquarter ...
IN THIS ISSUE: LIFE Goes On. Got an Urgent Project? Require Unusual Chemistry or Technology? Hydrazine. Industrial. Real The Archimica Newsletter for the Pharmaceutical Industry Spring 2023 LIFE Goes On. ...
Announces completion of 1,5 Mio. Euro investment in continuation of its support of proven drugs using its high-compliance large-volume API capability with challenging chemistry and technology Lodi, February 3, ...
September 5, 2022 Archimica continues Expansion - Announces completion of its 2 Mio. Euro Investment Upgrade of its Multi-Purpose Manufacturing Capacity Archimica has started the operation of its state-of-the art ...
Archimica is happy to announce the availability of small-to large scale industrial quantities of αGPC100 (L-α-Glycerophosphoryl-choline). Since decades Archimica is a leading manufacturer of deacylated phospholipids such as L-α-Glycerophosphoryl-choline (GPC) ...
Hydralazine Hydrochloride is a highly effective drug use in treatment of severe hypertension and congestive heart failure. It is proven since many years mainly as second line and/or important part ...
L-α-Glycerophosphoryl-ethanolamine, Synthesis Grade (GPE SG, see also Archimica´s API grade [Alpha-glycerylphosphorylethanolamine (GPE)] ) is a valuable advanced intermediate for the synthesis of lipids and antifungals. The high potential as intermediate ...
July 22, 2021 Archimica announces completion of its 1,2 Mio. Euro Investment Expansion of its Multi-Purpose Manufacturing Capacity on CPHI North America Archimica has started the operation of its expanded ...
25 May 2021 Archimica invests 1,3 Mio. Euro in Expansion of Process Development Capacity Archimica has started the operation of its expanded development laboratories at its Lodi (Italy) site. A ...